Search Results

An in-depth analysis of Ireland's €93.8 billion pharmaceutical and medical exports to non-EU markets. Examining trade data across the United States, UK, Switzerland, and Asia-Pacific, key manufacturing clusters in Cork, Dublin, and Limerick, and the strategic outlook for 2026.

As direct-to-patient dispensing platforms like LillyDirect expand across the UK and digital healthcare alters prescription delivery, community pharmacists in Ireland and Great Britain are adapting. This critical analysis examines the impact of mail-order platforms, recent regulatory shifts in Ireland, and how local chemists are pivoting to clinical primary care services.

An in-depth clinical and market analysis of GLP-1 therapeutics in 2026, examining central brain reward circuit mapping from the University of Virginia, Phase 3 oral small-molecule data for Orforglipron, Retatrutide triple-agonist efficacy, and systemic cardiometabolic benefits.

An in-depth analysis of where US pharmaceutical tariff policies stand in mid-2026 under the Trump administration, analyzing recent CSO export data, inventory stockpiling corrections, MFN agreements, and Ireland’s strategic biopharma position.

Jefferies has revised its debut-quarter US sales estimate for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) down to $71 million - well below the Wall Street consensus of $130 million and sharply below its own prior estimate of $85 million. With weekly prescriptions hovering around 20,000 and Novo Nordisk's oral Wegovy outpacing it on trajectory, the first oral non-peptide GLP-1 for obesity is generating a very different story than the hype suggested.

Eli Lilly has successfully brought its LillyDirect service to the UK. Adapted to comply with strict local regulations, the service partners with regulated healthcare organizations to offer secure, anti-counterfeit delivery of high-demand therapies like Mounjaro directly to patients' doors.

With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.

Met Éireann has issued a Status Yellow High Temperature Warning for Ireland. Here is everything you need to know: how to protect yourself and your family, what to eat and drink, what to keep at home, and the key precautions recommended by HSE and public health experts.

Novo Nordisk commits €432 million to upgrade its Athlone facility, expanding manufacturing capacity for oral GLP-1 weight-loss and diabetes treatments.

The Health Service Executive (HSE) is facing intense budgetary pressure as clinical demand for GLP-1 obesity medications skyrockets. We break down the restrictive funding, the "dreadful dichotomy" of access, and the surge in illegal online sales.

A recent PwC report warns that US commercial healthcare costs will surge by 9% in 2027. We compare the driving forces behind this unprecedented American inflation with the pressures currently facing the Irish healthcare system.

The June 2026 country-by-country disclosures revealed that Eli Lilly paid $6.6 billion in Irish corporation tax-double its US federal liability. We analyze why Ireland remains the ultimate hub for global pharma despite the OECD 15% minimum tax.

From AI-powered diagnostics to digital therapeutics and connected devices - these 10 companies are reshaping healthcare in Ireland and hiring right now. Here's where the future health jobs are and how to land one.

Eli Lilly has committed over €2 billion to its Raheen biomanufacturing campus - the largest single pharma investment in Irish history. Here's what it means for your career in 2026.